SCHEDULE 13G/A: Solas Capital Management and Frederick Golden Maintain Significant Stake in Fennec Pharmaceuticals, Holding 8.2% of Common Shares
Beneficial Ownership Report
Solas Capital Management, LLC and Frederick Tucker Golden have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 8.2% in Fennec Pharmaceuticals Inc. as of December 31, 2024.
Summary
- Solas Capital Management, LLC and Frederick Tucker Golden jointly reported beneficial ownership of 2,250,919 common shares of Fennec Pharmaceuticals Inc.
- This ownership represents 8.2% of Fennec Pharmaceuticals Inc.'s common stock outstanding.
- The percentage is based on 27,432,234 shares of common stock outstanding as of November 5, 2024, as reported by Fennec Pharmaceuticals Inc. in its Form 10-Q filed on November 8, 2024.
- Solas Capital Management, LLC, an investment adviser, serves as the investment manager to two private funds and as sub-adviser to another private fund, which hold these securities.
- Frederick Tucker Golden, as Portfolio Manager of Solas Capital Management, LLC, has the power to exercise investment and voting discretion over these shares.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of beneficial ownership. A score of 6 indicates a slightly positive sentiment as it confirms continued significant institutional investment in the company, which can be viewed favorably by the market, but it does not contain performance-related news.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant ownership stake by an institutional investor in a publicly traded pharmaceutical company. It reflects continued investment interest from Solas Capital Management, LLC and Frederick Tucker Golden in Fennec Pharmaceuticals Inc.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially signaling confidence or continued interest in the company.
Key Dates
| Date | Description |
|---|---|
| 2024-11-05 | Date as of which 27,432,234 common shares of Fennec Pharmaceuticals Inc. were outstanding, as reported in the Issuer's Form 10-Q. |
| 2024-11-08 | Date Fennec Pharmaceuticals Inc. filed its Form 10-Q with the SEC, reporting shares outstanding. |
| 2024-12-31 | Date of event which requires the filing of this statement, reflecting the beneficial ownership position. |
| 2025-02-14 | Signature date of the Schedule 13G Amendment No. 2 filing by Solas Capital Management, LLC and Frederick Tucker Golden. |
Keywords
Fennec Pharmaceuticals, Solas Capital Management, Frederick Tucker Golden, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor, Common Shares, Investment Adviser, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.